(Q53306425)

13 May 2018

title

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. (English)

1 reference

13 May 2018

1 reference

Engel J

1

1 reference

13 May 2018

Eckel R

2

1 reference

13 May 2018

Schubert-Fritschle G

3

1 reference

13 May 2018

Kerr J

4

1 reference

13 May 2018

Kuhn W

5

1 reference

13 May 2018

Diebold J

6

1 reference

13 May 2018

Kimmig R

7

1 reference

13 May 2018

Rehbock J

8

1 reference

13 May 2018

Hölzel D

9

1 reference

13 May 2018

publication date

1 December 2002

1 reference

13 May 2018

European Journal of Cancer

published in

1 reference

13 May 2018

volume

38

1 reference

13 May 2018

issue

18

1 reference

13 May 2018

page(s)

2435-2445

1 reference

13 May 2018

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Ovarian cancer. Survival and treatment differences by age

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

An overview in the treatment of advanced ovarian cancer. MRC Gynaecological Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Advanced epithelial ovarian cancer: 1998 consensus statements

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Are increasing 5-year survival rates evidence of success against cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Descriptive epidemiology of ovarian cancer in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Declining cancer rates in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

Randomized trials or observational tribulations?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900495-1

7 January 2021

10.1016/S0959-8049(02)00495-1

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018